| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ACAN; AGC1; AGCAN; Aggrecan 1; CSPG1; CSPGCP; JSCATE; Large aggregating proteoglycan; mcspg; mgsk16; MSK 16; SEDK;;Aggrecan |
| WB Predicted band size | Calculated MW: 261 kDa ; Observed MW: 250 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human Aggrecan |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3-4篇关于Aggrecan抗体的代表性文献摘要(信息基于公开研究整理)：
---
1. **文献名称**：*Aggrecanase cleavage of aggrecan is a prominent feature of human osteoarthritis*
**作者**：Pratta MA, et al.
**摘要**：研究利用抗Aggrecan抗体检测骨关节炎(OA)患者关节液中Aggrecan的降解片段，发现Aggrecan酶(ADAMTS)的活性与OA病理进展密切相关，揭示了Aggrecan抗体在疾病生物标志物研究中的应用价值。
2. **文献名称**：*Monoclonal antibodies against human aggrecan and their epitope specificities*
**作者**：Caterson B, et al.
**摘要**：作者开发了多种针对Aggrecan核心蛋白及糖胺聚糖链的单克隆抗体(如克隆KO602、BC-13)，并阐明了不同抗体识别的表位差异，为研究Aggrecan结构功能及疾病诊断提供工具。
3. **文献名称**：*Antibody-induced arthritis in mice by aggrecan immunization*
**作者**：Glant TT, et al.
**摘要**：通过向小鼠注射抗Aggrecan抗体，成功建立类风湿性关节炎动物模型，证明Aggrecan抗体可直接引发关节炎症和软骨破坏，为研究自身免疫性关节炎机制提供实验依据。
4. **文献名称**：*Cartilage-specific deletion of aggrecan alters cartilage remodeling during postnatal development*
**作者**：Watanabe H, et al.
**摘要**：利用Aggrecan抗体进行组织学分析，发现Aggrecan缺失导致小鼠软骨发育异常，强调了Aggrecan在维持软骨稳态中的关键作用，并验证了抗体在组织特异性标记中的可靠性。
---
**注**：以上文献信息为简化概括，实际引用时需核对原文及期刊要求(如*Arthritis & Rheumatism*、*Journal of Biological Chemistry*等)。如需具体年份或DOI，可进一步提供。
**Background of Aggrecan Antibodies**
Aggrecan, a large proteoglycan, is a key component of the extracellular matrix (ECM) in cartilage and other connective tissues. It plays a critical role in maintaining tissue resilience by forming aggregates with hyaluronan and link proteins, creating a hydrated gel-like matrix that resists compressive forces. Aggrecan’s core protein contains numerous glycosaminoglycan (GAG) chains, primarily chondroitin sulfate and keratan sulfate, which contribute to its osmotic swelling properties. Degradation or loss of aggrecan is closely linked to cartilage degeneration in osteoarthritis, intervertebral disc disorders, and other musculoskeletal diseases.
Antibodies targeting aggrecan are essential tools for studying its expression, localization, and degradation in both research and diagnostic contexts. These antibodies often recognize specific epitopes on the core protein or GAG-attachment regions, enabling detection of intact aggrecan or its cleavage products (e.g., by matrix metalloproteinases or aggrecanases like ADAMTS-5). They are widely used in techniques such as immunohistochemistry, Western blotting, and ELISA to assess aggrecan levels in tissue samples, cell cultures, or synovial fluid.
Additionally, aggrecan antibodies aid in exploring pathological mechanisms, evaluating therapeutic interventions (e.g., chondroprotective drugs), and understanding developmental processes in cartilage formation. Monoclonal antibodies offer high specificity, while polyclonal versions may detect broader epitope ranges, useful for fragmented aggrecan. Their applications extend to regenerative medicine, where monitoring ECM restoration is critical for tissue engineering strategies.
×
